Member Info for stu485

JHFH,

So instead of putting down the shovel, you now have one in each hand and just keep digging that FCA hole deeper & deeper!

JHFH : Posts.

“Their failure to represent the company accurately to the market is again a total failure of duty. Vlad gets real time data from Prevail, they know HG-CT-1 works, they know its safe, MDA know its safe, they are testing the next patient”

Really !?

Either you or the company are skating on some very thin ice !… I suspect it’s you.

Seems when you’re stiffed financially, you don’t like it much at all. Maybe it’s a taste of your own medicine that you’ve been liberally prescribing to others on this board for a number of years !

You make no attempt at answering the obvious question;

Q, Were all as JHFH has posted above and previously true facts, why would there be a need to offer such a deep discount in the placing ?

Look forward to your answer .

AIMO

Dhub,

For those with more than one brain cell , you’re just as transparent as JHFH.

I suggest all should take a quick read of your history , previous predictions and time frames.

AIMO

Tippy,

You appear to be deliberately overlooking the theme JHFH is portraying within his posts.

Yes selected and recruited can be different but whereas JHFH suggesting all swimmingly and no concern the company statement makes clear it’s a possibility there may never be a second patient.

Have another read of the RNS without emotional bias.

An aside.

Your all forgetting patient number one. Reflect a little and you’ll realize, your day’s not too bad even with JHFH’s posts.

Good luck No1.

AIMO

JHFH,

You might want to put that shovel down !

Yeah, quickly move off your first defence and onto another snippet of information that’s not public!

The company does not seem to agree with your most recent claim !

“the initial patient was infused with HG-CT-1 in February 2024 and, subject to a satisfactory outcome, a second patient will be recruited and treated as quickly as practical”

AIMO.

Mr Jinx,

I suspect JHFH will be having many more conversations with the FCA if true.

Personally i think his comments are simply a very transparent attempt to deflect from the big question of why such a massive discount was necessary.

AIMO

JHFh,

“Better offers were available “

So either you know that to be true and as such, i believe in possession of insider information OR your lying!

I suspect the later as a desperate defence of your continuing contrived and misleading narrative regarding funding.

Best I leave it for “others” to properly determine !

AIMO

Lotm,

Dont worry i’m sure it’ll be investigated properly and in detail.

AIMO

Yes HT .

You forgot to mention, similar trials mostly fail to become a useful treatment and that’s why first patient dose is unlikely to spark SP re-rate.

Should there actually be a first patient, then i genuinely have my fingers crossed Hemo’ can buck the trend and succeed where others have failed.

Good luck.

AIMO

JFH,

Which circus do you work at …clown !

First injection…and what ?

Big investor…where ?

AIMO

JFH,

Why don’t you give it a rest and stop trying to ensnare others with your twisted and eternally incorrect predictions!

The facts speak for themselves.

AIMO

Well, my trust in the company achieving it’s,

“non-dilutive financing” objective, announced in its June RNS, has timed out early.

I now expect a dilutive fund raise announcement, possibly nicely wrapped up in details of FDA approval on amendment and expansion of clinical trial IND.

The recent *professionals reaction to the Prevail RNS ,understanding what it is and more importantly, isn’t!

the PENN trial question, and the contrived shift in

sentiment here to the cliched and delusory,

merry-go-round of, “short term pain for long term gain”

i think all clearly signposts what’s now coming.

Were the “longterm gain” (that’ll soon be spouted ad nauseam by the gang),probable, then all fine…but it isn’t!

See durability in AML treatment response and trial to treatment success rates, please DYOR.

I’m sorry but i now believe the financial carrot remains firmly attached to an ever lengthening stick, with a rapidly dwindling number of Donkeys in unquestioning pursuit.

Hopefully for genuine LTH , the company prove me wrong and does not fail in its objective of realizing non-dilutive financing. It should be perfectly possible if industry savvy investors share in the company’s belief of their product candidate potentials.

Alas, I can’t see it.

*Ask JHFH to post the TW link again should you wish to fact check the particular professionals opinion.

I will not be responding.

AIMO

Ps Sorry gang, travel plan delayed a little but I’ll soon be gone 😉

Why am i leaving?

Well HT knows why I’ll soon be traveling and off grid for long periods.

This season the gang won’t though know my exact whereabouts! Those pesky Data Protection laws !?

Good luck all genuine investors.

To the others, there’s a new “Sheriff” in town who will be way more troublesome for your false narratives than i ever was, …hey JFH!?

BHold,

Your too smart for me! You’re 100% correct i am short .

Have a good weekend all and HK , that was a genuine thanks for at least trying.

AIMO

Ps. 5’4” !

HK,

There’s no shame in admitting a genuine mistake.

You we’re trying to answer the important question others only seek to avoid.

For that you have my thanks.

AIMO

HK,

Well that’s interesting but how about we stick to the department in PENN that would actually be conducting Car-T trials for AML and leave the “Gene therapy “ difficulties for another board where it might actually have some relevance!

I’ll wait for the company to offer an explanation thanks and leave the circus here to spout any nonsense they care to .

AIMO

Lost,

The below are facts not lies !

You’ve expressed your opinion and I’ve mine.

It’s not just me who’s concerned and that’s why I wouldn’t be surprised to see an RNS reach with further details regarding PENN’s involvement, to hopefully reassure.

Maybe even straight after JFH’s short squeeze today😉

BHold,

I’m 5’ 4” and don’t have any shorter mates !?

Half Year RNS.

“While Penn remains supportive and wishes to participate, several issues have delayed their proposed schedule.”

Stu Oct3rd 13:28

“Shareholders here are concerned whey PENN can’t/won’t schedule the H Car-T trials as Hemo’ had expected and that delays in trials is likely shortening and already limited cash runway”.

AIMO

Lostapound,

Yes that’s correct.

Can you please advise what the issues are and why the company only now “hopes” that PENN will actually participate at all ?

The answer is no , you can’t because there is no detail within the RNS announcement regarding the schedule issue.

I wonder why not !?

AIMO

HT, Chris, point taken.

He does need putting in his place on occasion .

Jfh,

You can stamp your feet in a childish tantrum and throw your mates under the bus in the process BUT you can’t change the facts of the matter!

Shareholders here are concerned whey PENN can’t/won’t schedule the H Car-T trials as Hemo’ had expected and that delays in trials is likely shortening and already limited cash runway.

You may seek to trivialise the facts, others will not.

AIMO

JFH,

So you’re answering on behalf of Mr I ?

He was wrong not you, thanks for the answer.

No delays, really?

Maybe you should have a chat with VS and suggest he retracts his statement on expectation of starting trials sooner (paraphrase).

You still confident of preliminary results of first three patients prior to Christmas!

You’re starting to unravel.

AIMO

Mr I,

You’re welcome.

It would be respectful to answer my very straightforward question though,..please!

AIMO

Ps Be careful in offering your personal financial advice .Something i will never knowingly do and suggest others DYOR and make independent assessment.